



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01K 67/00		A1	(11) International Publication Number: WO 00/51423
			(43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/US00/05454		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 March 2000 (03.03.00)			
(30) Priority Data: 60/122,961 3 March 1999 (03.03.99) US			
(71) Applicant (for all designated States except US): UNIVERSITY OF NEW MEXICO [US/US]; Patent Administration Office, Hokona Hall, Zuni Wing, Room 357, Albuquerque, NM 87131 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GOADE, Diane, E. [US/US]; 7601 Parkwood Drive, Northwest, Albuquerque, NM 87120 (US). KUSEWITT, Donna, F. [US/US]; 1405 Ridgecrest Drive, Southeast, Albuquerque, NM 87108 (US). NOFCHISSEY, Robert, A. [US/US]; 4303 Zuni Trail, S.W., Los Lunas, NM 87031 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agent: SLUSHER, Stephen, A.; Peacock, Myers & Adams, P.O. Box 26927, Albuquerque, NM 87125-6927 (US).			
(54) Title: HERPES SIMPLEX VIRUS REACTIVATION MODEL			
(57) Abstract Methods and systems for animal models of herpes simplex virus infections, for use in drug discovery, drug testing and research. Includes models of cutaneous herpes simplex viral infections, with reactivation by use of ultraviolet radiation. Following induction and resolution of primary infection, a drug to be tested is administered prior or subsequent to reactivation by use of ultraviolet radiation, including solar spectral radiation, to determine effectiveness of the drug to inhibit or limit reactivation infection. Also provided are methods for determining effectiveness of drugs to inhibit or limit primary infections, and methods for determining effectiveness of drugs, including topical preparations, as sunscreen agents, including ultraviolet-B specific radiation agents.			